I blend scientific rigor with humility and clear communication, believing that the best research is both collaborative and translational. As a PhD candidate in Bacteriology (conferral expected August 2025) with a focus on infectious disease and vaccine development, I bring hands-on experience in recombinant protein production, aseptic technique, molecular biology, and in vivo models for vaccine efficacy. Known for my adaptability and interpersonal ease, I thrive in cross-functional teams and contribute both technically and strategically to mission-driven science.
Miller, J.M., Ozyck, R.G., Pagano, P.L. et al. Rationally designed Mycoplasma gallisepticum vaccine using a recombinant subunit approach. npj Vaccines 9, 178 (2024). https://doi.org/10.1038/s41541-024-00978-x
Gavitt TD, Mara AB, Goodridge ML, Ozyck RG, Reinhardt E, Miller JM, Hunte M, Tulman ER, Frasca S Jr, Silbart LK, Geary SJ, Szczepanek SM. B cells oppose Mycoplasma pneumoniae vaccine enhanced disease and limit bacterial colonization of the lungs. NPJ Vaccines. 2022 Oct 31;7(1):130. doi: 10.1038/s41541-022-00556-z. PMID: 36310317; PMCID: PMC9618410.
Mara AB, Gavitt TD, Tulman ER, Miller JM, He W, Reinhardt EM, Ozyck RG, Goodridge ML, Silbart LK, Szczepanek SM, Geary SJ. Vaccination with Mycoplasma pneumoniae membrane lipoproteins induces IL-17A driven neutrophilia that mediates Vaccine-Enhanced Disease. NPJ Vaccines. 2022 Jul 29;7(1):86. doi: 10.1038/s41541-022-00513-w. PMID: 35906257; PMCID: PMC9336141.